HER2 targeting is a well-accepted treatment regimen for HER2 positive breast cancer, and HER1/EGFR targeting is commonly used in head and neck squamous cell carcinoma (HNSCC), where overexpression of EGFR occurs in 80% to 90% of tumors and is similarly associated with poor outcomes.2 The gene discussed is ERBB2; the disease is breast carcinoma.